drugset / Trial / NCT06925919
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase 1
Active not recruiting
40 enrolled
IDBiologics, Inc.
Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Timeline
- Start
- 2025-04-02
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDB-774 | Unknown | — | Intramuscular |
| Subject | IDB-898 | Unknown | — | Intramuscular |